{"analyses":[{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.03","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.11","paramType":"Hazard Ratio (HR)","paramValue":"0.86","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.70","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.59","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.25","upperLimit":"26.64","value":"20.9"},{"groupId":"OG001","lowerLimit":"23.82","upperLimit":"46.06","value":"33.02"},{"groupId":"OG002","lowerLimit":"14.59","upperLimit":"23.82","value":"19.09"},{"groupId":"OG003","lowerLimit":"27.83","upperLimit":"56.44","value":"42.81"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"376"},{"groupId":"OG002","value":"377"},{"groupId":"OG003","value":"374"}],"units":"Participants"}],"description":"Disease progression is defined as radiological or neurological/clinical progression (whichever occurs first); progression free survival (PFS) is the time interval between the date of randomization and the date of disease progression or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination. Radiological progression was defined as increase of contrast enhancing area on MRI or CT scans of more than 25% as measured by two perpendicular diameters compared to the smallest measurements ever recorded for the same lesion by the same technique. The appearance of new lesions with or without contrast enhancement Neurological/clinical progression was defined as:decrease in WHO performance status,deterioration of neurological functions,appearance of signs/symptoms of increased intracranial pressure,and/or start of corticosteroid or increase of corticosteroid dosage by 50% for control of neurological symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Including 2 randomized arms: Arm RT alone and Arm RT followed by adjuvant TMZ","id":"OG000","title":"Absence of Concomitant TMZ"},{"description":"Including 2 randomized arms: Arm TMZ/RT and Arm TMZ/RT followed by adjuvant TMZ","id":"OG001","title":"Presence of Concomitant TMZ"},{"description":"Including two randomized arms: Arm RT alone and Arm TMZ/RT","id":"OG002","title":"Absence of Adjuvant TMZ"},{"description":"Including to 2 randomized arms: Arm RT followed by adjuvant TMZ and Arm TMZ/RT followed by adjuvant TMZ","id":"OG003","title":"Presence of Adjuvant TMZ"}],"paramType":"MEDIAN","populationDescription":"This trial studied separately two questions 1) effect of concomitant TMZ 2) effect of adjuvant TMZ. The 4 randomized arms were combined before analysis. Absence of concomitant TMZ including Arm RT alone \\& Arm RT followed by adjuvant TMZ. Presence of concomitant TMZ including Arm TMZ/RT \\& Arm TMZ/RT followed by adjuvant TMZ. Absence of adjuvant TMZ including Arm RT alone \\& Arm TMZ/RT. Presence of adjuvant TMZ including Arm RT followed by adjuvant TMZ \\& Arm TMZ/RT followed by adjuvant TMZ","reportingStatus":"POSTED","timeFrame":"from randomization till the date of disease progression or death (time till death is up to 10.9 years after patient enrollment in the study)","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}